Zai Lab Expects First-Half 2026 Net Profit of HK$486M-525M on Strategic Partnerships

Zai Lab (02142) expects first-half 2026 profit of HK$486 million to HK$525 million (USD 62-67 million) as of June 30, with revenue projected at HK$941 million to HK$980 million (USD 120-125 million). The growth is driven by ongoing strategic partnerships with global pharmaceutical companies, product licensing collaborations, and milestone payments from prior partnerships, alongside strong performance from Nuona Biologics' antibody business.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments